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The effects of a few cytotoxic organogold(III) compounds on ovarian A2780 human cancer cells
were investigated in comparison to cisplatin and oxaliplatin. The tested compounds produced
significant antiproliferative effects and promoted apoptosis to a greater extent than platinum
drugs while causing only modest cell cycle modifications. The mechanistic implications of these
findings are discussed: mitochondrial pathways are proposed to be directly involved in the
apoptotic process in relation to selective inhibition of thioredoxin reductase.
Introduction
In the past few years, second-generation gold(III)
compounds have greatly attracted the interest of re-
searchers for their encouraging antitumor properties.1-3
Indeed, a variety of structurally different gold(III)
compounds such as gold(III) porphyrins,4 gold(III) dithio-
carbamates,5 and gold(III) polyamines6 were shown to
be chemically suitable for pharmacological testing and
to produce important cytotoxic effects when assayed in
vitro on various human tumor cell lines; for some of
them promising in vivo results have been obtained as
well.7-9 Also, a number of organogold(III) compounds
were recently reported to exhibit favorable chemical and
biological profiles; in particular, we found that a few
organogold(III) compounds, bearing the bipyridyl motif,
are endowed with outstanding anticancer properties
against selected human tumor cell lines and thus
deserve further pharmacological investigations.10,11
Yet, very little is known concerning the molecular
mechanisms underlying the pharmacological effects of
gold(III)-based antitumor metallodrugs.1 The initial
efforts toward the synthesis and the biological evalua-
tion of anticancer gold(III) compounds were mainly
driven by their chemical analogy with platinum(II)-
based drugs. It was postulated that the biological actions
of gold(III) compounds might be a consequence of direct
DNA damage as it is the case for cisplatin and its
analogues. However, in contrast to general expectations,
a number of subsequent experimental results suggested
that gold(III) compounds exert their biological and
antiproliferative effects through mechanisms that are
substantially distinct from those of platinum(II) com-
pounds.1 Various gold(III) and organogold(III) com-
pounds were shown to interact very weakly with calf
thymus DNA and to produce only modest modifications
of the double helix.12
To further elucidate these issues and describe the
main cellular effects induced by novel organogold(III)
compounds, new experiments were carried out in our
laboratory. Specifically, the following organogold(III)
compounds were selected for the present investigation:
[Au(bipydmb-H)(OH)][PF6] (1), Au(bipydmb-H)(2,6-xyli-
dine-H)][PF6] (2) (in which bipydmb ) 6-(1,1-dimethyl-
benzyl)-2,2′-bipyridine), and [Au(pydmb-H)(AcO)2] (3) (in
which pydmb ) 2-(1,1-dimethylbenzyl)-pyridine) (see
Chart 1). These compounds were previously character-
ized and found to cause significant antiproliferative
effects on the human tumor cell lines A2780, MCF7,
HT29, and A549.10,11 We analyze here the effects
produced by these organogold(III) compounds on ovarian
A2780 carcinoma cells, either sensitive (A2780/S) or
resistant (A2780/R) to cisplatin, in terms of cytotoxicity,
cell cycle modifications, and induction of apoptosis. For
comparison purposes, parallel experiments were carried
out with cisplatin (CDDP) and oxaliplatin (OHP), under
identical solution conditions. Our investigations are
principally aimed at describing the cellular responses
to organogold(III) compounds in order to gain specific
mechanistic information on these novel anticancer
agents.
Results
Cytotoxicity of Organogold(III) Compounds. The
antiproliferative effects, in vitro, of the mentioned
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Chart 1. Chemical Structures of the Tested
Organogold(III) Compounds
6761J. Med. Chem. 2005, 48, 6761-6765
10.1021/jm050493o CCC: $30.25 © 2005 American Chemical Society
Published on Web 09/24/2005
organogold(III) compounds were measured as described
in the Experimental Section. The concentrations re-
quired to inhibit growth of A2780/S and A2780/R cells
by 50% (IC50), following 48 h incubation, were deter-
mined (Table 1). Notably, all three organogold(III)
compounds cause relevant antiproliferative effects with
IC50 values falling in the 1-10 íM range, thus being
comparable with cisplatin. Significant cross-resistance
effects were detected for these organogold(III) com-
pounds: the resistance factors measured in the A2780/R
line were 7.0 for 1, 2.3 for 2, and 2.6 for 3.
Cell Cycle and Apoptosis Analysis. After deter-
mination of their IC50 values, the three organogold(III)
compounds were presented to cell cultures at equitoxic
concentrations (drug concentrations were equal to the
respective IC50 values) and their effects analyzed by flow
cytometry, after 48 h incubation. Remarkably, no sig-
nificant modifications of the cell cycle phases were
observed under the present experimental conditions,
differently from the cases of cisplatin and oxaliplatin
(Figure 1A,B). However, a relatively intense sub-G1
peak appeared in organogold(III)-treated A2780/S cells,
that represents cells undergoing apoptosis. This latter
feature was far more evident for 2 and 3 than for 1. In
contrast, treatment of A2780 cells with larger amounts
of organogold(III) compounds (drug concentrations equal
to IC70 values were employed in this new series of
experiments, roughly corresponding to 5  IC50), for 48
h, resulted in deeply perturbed flow cytometry profiles,
most likely in relation to extensive cell death (data not
shown).
This led us to establish a further administration
scheme that might be a reasonable compromise between
the two above extremes. In the new scheme, A2780 cells
were treated for 4 h with drug concentrations matching
the IC70 values (5  IC50), followed by 20 h postincu-
bation in drug-free medium. Cells exhibiting apoptotic
fragmentation were detected by TUNEL assay. Percent-
ages of S, G1, G2 cell phases, and of apoptotic cells,
determined either by TUNEL assay or by sub-G1 peak
quantitation, in organogold(III) treated A2780/S and
A2780/R cells, are reported in Figure 2A and Figure 2B,
respectively.
In the new series of experiments, the cell cycle effects
of 1 turned out to be similar to those of OHP, with a
significant decrease of S phase; also, a concomitant
slight increase in G2 phase was noted. Pairwise, the
intensity of the sub-G1 peak was similar to OHP
whereas results of TUNEL were lower. The behavior of
compounds 2 and 3 was more similar to that of cisplatin;
increases of G2 and S/G2M phases were respectively
found for these compounds. However, 2 and 3 differed
markedly from cisplatin for the large increase of the sub-
G1 peak and for the high scores of the TUNEL test.
These results suggest that cells in the G2M phase are
the most susceptible to apoptosis induction. Significant
apoptotic breaks could be seen with compound 1 at IC70
values, after 48 h incubation but not after a 4 h
treatment, showing a clear dependence of the apoptotic
events on the exposure time. Treatment of A2780/R
cells, in accordance with the 4/20 h scheme, resulted in
accumulation of cells in the S-phase, that is particularly
evident for 3; in addition, we noticed, for compounds 1
and 3, the appearance of cells with significant DNA
fragmentation that are better evidenced by TUNEL
assay than by sub-G1 peak quantitation.
Overall, these experimental results reveal a great
apoptotic potential for all the investigated organogold-




CDDP 1.0 7.0 (7.0)
OHP 0.1 0.3 (3.0)
1 1.0 7.0 (7.0)
2 3.0 7.0 (2.3)
3 3.5 9.0 (2.6)
a Amount of drug necessary to inhibit the growth of parental
(A2780/S) and cisplatin-resistant (A2780/R) cells by 50% in 48 h.
Data are the means of two determinations; values in parentheses
indicate the ratio of IC50 of cisplatin-resistant cell line and IC50 of
parental sensitive cell line.
Figure 1. Cell cycle analysis. A2780/S (panel A) and A2780/R
(panel B) cells were treated with IC50 concentrations of the
various cytotoxic agents and processed at 48 h for flow
cytometric analysis as described in the Experimental Section.
Percentages of G0 /G1 phase, S phase, and G2 phase cells are
shown; percentages of sub-G1 cells are also reported. Data refer
to a representative experiment, repeated twice.
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(III) compounds in the presence of only modest cell cycle
alterations.
A further insight into the apoptotic potential of
organogold(III) compounds is provided by multipara-
metric flow cytometry determinations. Specifically, an
experiment was carried out in which cells or cell
fragments positive for apoptotic strand breaks (deter-
mined by TUNEL) were measured against the forward
scatter. Data are presented as bivariate histograms
(Figure 3) according to previous literature.13 In the case
of cells treated with the organogold(III) compounds,
profound increases in cells with a high signal for
apoptotic breaks were generally observed. Notably,
forward scatter data suggest dramatic morphological
changes in compound 2 treated A2780/S cells. Occur-
rence of extensive apoptosis is confirmed by direct
observation of cells at the microscope (Figure 4) where
bright fluorescence upon HOECHST 33342 staining is
indicative of nuclear fragmentation.
Discussion
The present study was mainly directed to gain further
mechanistic information on novel gold(III) metallodrugs;
specifically, we focused our attention on a few organ-
ogold(III) compounds that were recently reported to
display encouraging chemical and biological profiles as
possible cytotoxic and antitumor agents.
The cellular effects of these compounds on the refer-
ence ovarian A2780 human cell line were analyzed in
detail, by using different concentrations and different
administration schedules. These organogold(III) com-
pounds manifest relevant cytotoxic effects with IC50
values falling in the low micromolar range; nonetheless,
significant cross-resistance phenomena were detected
implying that the resistance mechanisms that are
effective toward platinum(II) compounds are still largely
effective toward gold(III) compounds. All the investi-
gated organogold(III) compounds, when presented at
concentrations matching their respective IC50 values,
did not produce significant alterations of the cell cycle
distribution. This behavior largely differs from that of
classical platinum(II) complexes that are known to
induce characteristic cell cycle alterations.14 It was also
evident that these organogold(III) compounds are able
to promote apoptosis to a greater extent than cisplatin
and oxaliplatin. These findings probably imply that
apoptosis is not a consequence of direct damage pro-
duced on nuclear DNA, as it is the case for platinum
compounds.
These initial results prompted us to implement a new
experimental protocol; the 4/20 h scheme was, in fact,
chosen to highlight early drug effects while minimizing
Figure 2. Cell cycle and apoptosis analysis. Percentages of
S, G1, G2 cell phases, and of apoptotic cells, determined either
by TUNEL assay or by sub-G1 peak quantitation, in organ-
ogold(III) treated A2780/S and A2780/R cells, are reported in
panel A and panel B, respectively. In this experiment, A2780
cells were treated for 4 h with drug concentrations matching
the IC70 values (5  IC50), followed by 20 h postincubation
in drug-free medium. Cells exhibiting apoptotic fragmentation
were detected by TUNEL assay.
Figure 3. Apoptosis analysis. Bivariate histograms, relative
to A2780/S (panel A) and A2780/R (panel B) cells, are shown
for control cells and cells treated with IC70 drug concentrations
for 4 h followed by a 20 h postincubation in drug-free medium.
Apoptotic breakage data (by TUNEL assay) are plotted against
forward scatter.
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late effects such as secondary necrosis and/or apoptosis,
resulting from lethal mitosis. DNA cleavage into high
molecular weight fragments (HMW) and the appearance
of oligonucleosomes (LMW) characterize the apoptotic
process. The rate of generation and the abundance of
HMW fragments can vary significantly according to the
apoptotic agent used, the duration of the stimulus, and
the cell type considered.15 High values of the TUNEL
test were obtained with compounds 2 and 3, in sensitive
cells, and with all organogold(III) compounds, in resis-
tant cells. In all cases, the increases of the sub-G1 peak
are less pronounced. These observations are suggestive
of extensive DNA cleavage into high molecular weight
fragments associated with weak chromatin condensa-
tion (see Figure 4). The lower values of hypodiploidity
might be indicative of the lack of low molecular weight
fragments responsible for the emission of apoptotic
bodies.15 Thus, these results highlight a great proapo-
ptotic potential for these novel organogold(III) com-
pounds; this interpretation was further supported by
multiparametric flow cytometry determinations and by
direct observation at the microscope.
The above observation prompted us to consider al-
ternative pathways for induction of apoptosis by orga-
nogold(III) drugs. An attractive hypothesis is that
apoptosis is induced by direct activation of a mitochon-
drial pathway. Indeed, over the past few years, mito-
chondria have become known for promoting apoptosis
through release of cytochrome c and other proapoptotic
factors during mitochondria permeability transition or
via other release mechanisms.16 Rigobello et al. have
recently provided further experimental support for the
linkages existing among the thioredoxin reductase/
thioredoxin system, the mitochondrial membrane per-
meability transition, and selective metal toxicity.17 In
collaboration with the group of Alberto Bindoli we have
recently shown that various gold(I) and gold(III) com-
pounds as well as other toxic agents behave as specific
inhibitors of mitochondrial thioredoxin reductase; in
particular, the effects of 1, 2, and 3 as inhibitors of
thioredoxin reductase were evaluated.18 The measured
IC50 values obtained for thioredoxin reductase inhibi-
tion, reported in Table 2, suggest that these compounds
are indeed highly selective inhibitors of this crucial
selenoenzyme although less potent than auranofin. For
comparison purposes, inhibition produced by cisplatin
was also measured and found to be orders of magnitude
lower.
These results strongly qualify thioredoxin reductase
as a probable target for novel organogold(III) com-
pounds. Although the effects of 1, 2, and 3 on the
mitochondrial functions and, specifically, on the induc-
tion of mitochondrial swelling are less pronounced than
those of other toxic metal ions, e.g., cadmium, it is very
likely that the observed mitochondrial alterations may
eventually lead to release of cytotochrome c, thus
initiating the apoptotic process. However, gold com-
pounds are scarcely effective on mitochondrial respira-
tion, at variance with metal ions and metal complexes
that exhibit a marked inhibition. This suggests that,
while the various metal ions act on a number of different
targets, gold compounds are highly specific and their
action seems to be restricted to a single target identified
as the mitochondrial isoform of thioredoxin reductase18
In conclusion, we have shown that a few novel
organogold(III) compounds produce relevant cytotoxic
and apoptotic effects on the reference A2780 cell line,
either sensitive or resistant to cisplatin, without affect-
ing importantly the cell cycle distribution. The scarce
effects produced on the cell cycle and the reported poor
binding toward purified DNA in vitro led us to consider
nonclassical pathways for induction of apoptosis. Since
these compounds behave as strong and selective inhibi-
tors of mitochondrial thioredoxin reductase, we propose
that a direct interference with mitochondrial functions
might explain the observed large proapoptotic effects
and the relevant antiproliferative effects.
Experimental Section
Materials. Sterile tissue-culture plates and other tissue-
culture plastic wares were purchased from Corning (U.S.A.).
Dimethyl sulfoxide (DMSO) and propidium iodide (PI) were
bought from Sigma, and Hoechst 33342 was bought from
Calbiochem-Behring Corp. (U.S.A.). The in situ cell death
detection kit and fluorescein were purchased from Roche
Diagnostics Corp. (U.S.A.). Human ovarian carcinoma sensi-
tive (A2780/S) and its cisplatin-resistant clone (A2780/R) were
cultured in RPMI 1640 (Euroclone Ltd, U.K.) supplemented
with 10% fetal calf serum (FCS, Euroclone Ltd, U.K.). Cell
lines were grown in humidified 5% CO2 at 37 °C and were
screened for mycoplasma; cells were split twice a week by
trypsinization (trypsin 0.05%/EDTA 0.02% in PBS, from
Euroclone Ltd, U.K.). [Au(bipydmb-H)(OH)][PF6], [Au(pydmb-H)-
(AcO)2], and [Au(bipydmb-H)(2,6-xylidine-H)][PF6] were syn-
thesized according to reported procedures in refs 19, 20, and
21; cisplatin (CDDP) and oxaliplatin (OHP) were obtained from
Teva Pharma Italia (Milano, Italy) and Sanofi-Synthelabo
(Milano,Italy), respectively. The stock solutions (10-2 M) of
compounds were prepared by dissolving the compounds in 1
mL of DMSO; CDDP and OHP stock solutions (10-2 M) were
prepared in sterile bidistilled water.
Figure 4. Apoptotic cell morphology evaluation by Hoechst
33342 staining. A2780/S and A2780/R cells were treated
according to the 4/20 h scheme and stained with Hoechst 33342
dye as described in the Experimental Section. The morphology
of untreated (A) and compound 2 treated (B) A2780/S cells is
shown.
Table 2. Inhibitory Effects of Organogold(III) Compounds on
Mitochondrial Thioredoxin Reductase
CDDP Auranofin Aubipy AuXil Aupy
IC50 (íM) 36.0 0.020 0.28 0.21 1.42
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Cytotoxicity Assay. The cytotoxic effects were checked by
count of the cells grown in 25 cm2 plates. Cells were seeded in
tissue-culture plates at 5  104 cells/mL (total volume 10 mL)
and incubated overnight. Standard drugs and compounds were
diluted to desired concentrations in RPMI 1640 medium, added
to plates, and incubated for 48 h. At the end of the incubation,
the medium was decanted and the IC50 values (drug concen-
tration inhibiting cell growth by 50%) were determined by cell
counting (model D Coulter counter, Coulter electronics, Ltd,
Luton, Bedfordshire, England).
Cell Cycle Analysis. A2780/S and A2780/R cells were
exposed to concentrations of the test compounds equal to IC50.
At 24 h and 48 h, cells were fixed in 70% ice-cold ethanol and
stored at 4 °C. Cells were then rehydrated in PBS (phosphate
buffered saline) and stained in propidium iodide (PI, 50 íg/
mL) solution containing RNase A (5 units/mL) for 30 min.22
PI-stained cells were analyzed for DNA content with a FAC-
Star cell sorter (Becton-Dickinson, Mountain View, CA)
equipped with an argon ion laser (model Innova 90, Coherent,
Palo Alto, CA) operating at 500 mW output at 488 nm. The
red fluorescence emitted by PI was collected by a 620 nm long-
pass filter, as a measure of the amount of DNA-bound PI, and
displayed on a linear scale. Data from 20 000 cells were
analyzed with forward and scattered light, and red fluores-
cence was recorded with Consort 30 software. Cell cycle
distribution was determined on a linear scale. The percentage
of cells in cycle phases was determined using WinMDI 2.8
Windows Multiple Document Interface Flow Cytometry Ap-
plication (Cylchred Windows 95, version 1.02).
TUNEL Assay for Identification of Apoptotic Cells.
Apoptotic DNA fragmentation was monitored based on fluo-
rescent nucleotide-tagging of 3′-OH ends with terminal deoxy-
nucleotidyl transferase (TdT) followed by cytofluorimetric
detection. Briefly, A2780/S and A2780/R cells were exposed
to concentrations of the test compounds equal to IC70 (at 48
h) for 4 h and postincubated in drug-free medium for an
additional 20 h. Aliquots of 2  107 drug-treated and control
cells were fixed with 1% paraformaldehyde (Sigma) in PBS at
room temperature for 15 min′. Fixed cells were washed with
PBS, resuspended in cold PBS, mixed with cold (-20 °C)
absolute ethanol (70% final concentration), and stored at 4 °C
in the dark. Cells were washed twice with cold PBS, and pellets
were resuspended in 50 íL of TUNEL reaction mixture (in
situ cell death detection kit, fluorescein, from Roche Kit No.
1-684-795) and incubated for 60 min at 37 °C in a humidified
atmosphere in the dark. For each cell line, a parallel reaction
without the enzyme was run to provide background staining.
Finally, cells were washed with PBS and counterstained in
1.0 mL of 5.0 íg/mL PI in PBS. Fluorescein isothiocyanate
(FITC) and PI fluorescence emissions were collected through
a 525-530 filter and 620 nm long-pass filter, respectively. Data
from 20 000 cells were analyzed with forward and scattered
light, and green and red fluorescence were recorded with
Consort 30 software. The percentage of apoptotic cells was
determined using WinMDI 2.8.
Apoptotic Cell Morphology Evaluation by Hoechst
33342 Staining. A2780/S and A2780/R cells were harvested
at 20 h following 4 h exposure to 48 h IC70 values of the test
compounds; control cells and treated cells were collected,
centrifuged, and stained with Hoechst 33342 (2 íg mL-1). After
staining, morphology was determined by examining the cytospin
slides using fluorescence microscopy interfaced with a com-
puterized image analysis system.
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